The application of nanotechnology in immune checkpoint blockade for cancer treatment

&NA; Cancer immunotherapy, which could utilize the host's immune system to kill tumor cells, has great potential in long‐term inhibition of tumor growth and recurrence compared to chemotherapy and radiotherapy. As we know, tumors exhibit powerful adaption to escape the destruction of immune system at the late stage of diseases due to overactivation of immune checkpoint pathways which function as natural “brakes” for immune responses. The newly emerging immune checkpoint inhibitors are regarded as the breakthrough for cancer immunotherapy as they can re‐boost the host's immune system by restoring T cells function and promoting cytotoxic T lymphocytes (CTLs) responses. However, there is still scope for improvement in enhancing the clinical efficacy and reducing side effects of these immune modulators. In this review, we mainly introduce the basic mechanisms of the immune checkpoint pathways and outline the recent successes of immune checkpoint blockade (ICB) therapy in combination with nanoparticle delivery system. Furthermore, the underexplored potential in application of nanotechnology to enhance the efficacy of immune checkpoint therapy and overcome the limits of immune checkpoint inhibitors is also discussed. Graphical Abstract Figure. No caption available. HighlightsThe basic mechanisms of immune checkpoint pathwaysImmune checkpoint blockade therapy in combination with nanoparticle delivery systemThe potential of nanotechnology to enhance immune checkpoint therapeutic efficacy

[1]  Koichi Araki,et al.  Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.

[2]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[3]  Christopher M. Jackson,et al.  Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.

[4]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[5]  K. Roy,et al.  Engineering nanoparticles to overcome barriers to immunotherapy , 2016, Bioengineering & translational medicine.

[6]  Zhen Gu,et al.  Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. , 2016, Nano letters.

[7]  Zhen Gu,et al.  Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody , 2016, Advanced materials.

[8]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[9]  D. Littman Releasing the Brakes on Cancer Immunotherapy , 2015, Cell.

[10]  R. Herbst,et al.  Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.

[11]  Shi Jiao,et al.  A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors , 2018, Nature Communications.

[12]  Axel Hoos,et al.  Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.

[13]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[14]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[15]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[16]  L. Zitvogel,et al.  Trial watch: IDO inhibitors in cancer therapy , 2014, Oncoimmunology.

[17]  A. Nezos,et al.  CD40/CD40L signaling and its implication in health and disease , 2009, BioFactors.

[18]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[19]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[20]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[21]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[22]  Song Li,et al.  Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier , 2017, Acta Pharmacologica Sinica.

[23]  Zhuang Liu,et al.  In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy , 2018, Science Translational Medicine.

[24]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[25]  Wenbin Lin,et al.  Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy. , 2018, Journal of the American Chemical Society.

[26]  Enzo Di Fabrizio,et al.  Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.

[27]  Qian Yang,et al.  Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma , 2014, International journal of nanomedicine.

[28]  J. Allison,et al.  Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine , 2015, Proceedings of the National Academy of Sciences.

[29]  Yi Yan Yang,et al.  Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing , 2015, Advanced healthcare materials.

[30]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[31]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[32]  G. Prendergast,et al.  Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.

[33]  Baolan Li,et al.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer , 2015, Scientific Reports.

[34]  G. Anderson,et al.  Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.

[35]  H. Kohrt,et al.  Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.

[36]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[37]  R. Coffman,et al.  Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells , 2016, Proceedings of the National Academy of Sciences.

[38]  Shiladitya Sengupta,et al.  Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy. , 2016, ACS nano.

[39]  P. O'dwyer,et al.  Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. , 2013 .

[40]  Zhuang Liu,et al.  Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. , 2017, ACS nano.

[41]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[42]  Zhaocai Zhou,et al.  Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. , 2016, Nano letters.

[43]  S. Son,et al.  Elimination of established tumors with nanodisc-based combination chemoimmunotherapy , 2018, Science Advances.

[44]  Conglian Yang,et al.  Biomimetic Nanovesicles for Enhanced Antitumor Activity of Combinational Photothermal and Chemotherapy. , 2018, Molecular pharmaceutics.

[45]  Ross A Soo,et al.  De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.

[46]  M. Curran,et al.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity , 2015, Front. Oncol..

[47]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[48]  J. Moffett,et al.  Tryptophan and the immune response , 2003, Immunology and cell biology.

[49]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[50]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[51]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[52]  Yaping Li,et al.  Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment , 2018, Advanced materials.

[53]  M. Hemann,et al.  A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. , 2015, Journal of the American Chemical Society.

[54]  W. Hennink,et al.  Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. , 2015, Biomaterials.

[55]  Jens-Peter Volkmer,et al.  Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.

[56]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[58]  Shu-Ying Liu,et al.  MgAl-layered double hydroxide nanoparticles co-delivering siIDO and Trp2 peptide effectively reduce IDO expression and induce cytotoxic T-lymphocyte responses against melanoma tumor in mice. , 2017, Journal of materials chemistry. B.

[59]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[60]  S. Rosenberg,et al.  Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade , 2005, The Journal of Immunology.

[61]  M. Valsecchi Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[62]  G. Gibney,et al.  Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. , 2014 .

[63]  R. Govindan,et al.  Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Uprichard The therapeutic potential of RNA interference , 2005, FEBS Letters.

[65]  John G. Doench,et al.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.

[66]  L. Martiny,et al.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.

[67]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[68]  Napoleone Ferrara,et al.  Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.

[69]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[70]  Huan Wang,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[71]  Zhen Gu,et al.  In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy , 2017, Nature Biomedical Engineering.

[72]  R. Weichselbaum,et al.  Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. , 2016, Journal of the American Chemical Society.

[73]  Ligeng Xu,et al.  Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy , 2016, Nature Communications.

[74]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[75]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[76]  Quanyin Hu,et al.  Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. , 2018, Nano letters.

[77]  Jinming Yu,et al.  PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.

[78]  Hao Cheng,et al.  PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy , 2018, Advanced materials.

[79]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[80]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[81]  H. Schneider,et al.  CD28 and CTLA‐4 coreceptor expression and signal transduction , 2009, Immunological reviews.

[82]  Ronnie H. Fang,et al.  Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity , 2017, Advanced materials.

[83]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[84]  M. Drutskaya,et al.  TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. , 2017, Cytokine.

[85]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[86]  I. Kwon,et al.  Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. , 2017, ACS nano.

[87]  Charles Pelizzari,et al.  Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy , 2018, Nature Biomedical Engineering.

[88]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[89]  Ping Yang,et al.  Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. , 2013, Clinical lung cancer.

[90]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Tasuku Honjo,et al.  Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.

[92]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[93]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[94]  I. Weissman,et al.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity , 2017, Proceedings of the National Academy of Sciences.

[95]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[96]  P. Scherle,et al.  Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. , 2009, Current cancer drug targets.

[97]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[98]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[99]  Quanyin Hu,et al.  Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. , 2016, ACS nano.

[100]  Ligeng Xu,et al.  Immunological Responses Triggered by Photothermal Therapy with Carbon Nanotubes in Combination with Anti‐CTLA‐4 Therapy to Inhibit Cancer Metastasis , 2014, Advanced materials.

[101]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[102]  A. Jimeno,et al.  Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies , 2012, Investigational New Drugs.

[103]  J. Wolchok,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[104]  Jun Wang,et al.  Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[105]  R. Weichselbaum,et al.  Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. , 2016, Journal of the American Chemical Society.

[106]  Drew M. Pardoll,et al.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.

[107]  Yichao Chen,et al.  An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy , 2016, Nature Communications.

[108]  J. Drijfhout,et al.  Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. , 2014, Vaccine.

[109]  Conglian Yang,et al.  Bone Marrow Dendritic Cells Derived Microvesicles for Combinational Immunochemotherapy against Tumor , 2017 .

[110]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[111]  Y. Kienast,et al.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.

[112]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[113]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[114]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[115]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[116]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[117]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[118]  A. Ribas,et al.  SnapShot: Immune Checkpoint Inhibitors. , 2017, Cancer cell.

[119]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[120]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[121]  J. Moon,et al.  Designer vaccine nanodiscs for personalized cancer immunotherapy , 2016, Nature materials.

[122]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[123]  Benjamin G. Bitler,et al.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. , 2016, Cell reports.

[124]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[125]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[126]  A. Nel,et al.  Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression , 2017, Nature Communications.

[127]  T. MacDonald,et al.  The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma , 2014, Journal of Immunotherapy for Cancer.